max(38.13±3.33)、(40.52±3.69)μg/L;AUC0-τ(1 688.45±302.38)、(1 399.88±376.44)min·μg/mL;AUC0-∞(1710.61±309.40)、(1 417.29±383.21)min·μg/mL;t1/2(30.92±6.41)、(22.37±7.59)h。結(jié)論 泮托拉唑鈉對(duì)映體在大鼠體內(nèi)的藥動(dòng)學(xué)存在立體選擇性特征,為臨床合理應(yīng)用手性藥物泮托拉唑鈉提供參考。;Objective To establish an HPLC method to determine pantoprazole sodium enantiomers in plasma, and study its pharmacokinetics in rats. Methods Pantoprazole sodium and phenacetin internal standard were extracted by liquid-liquid extraction and separated on Chiralcel OJ-RH column (250 mm×4.6 mm, 5 μm), with 20 mmol/L natrium biphosphoricum (containing 0.01% phosphoric acid)-acetonitrile (22:78) as mobile phase. The column temperature was set at 40℃, and the analytical wavelength was 288 nm with flow rate as 1.0 mL/min. Rats were tail iv administered with racemic pantoprazole sodium 16 mg/kg, and L- and D-pantoprazole sodium in plasma were determined by HPLC-UV method. DAS 2.0 software was used to calculate the pharmacokinetic parameters. Results The calibration curve was linear over the concentration range of 0.156-40.00 μg/mL with a sensitivity of 0.156 μg/mL as the limit of quantification. Main pharmacokinetic parameters were as following:Cmax for L- and D-pantoprazole sodium were (38.13±3.33) and (40.52±3.69) μg/L; AUC0-τ were (1 688.45±302.38) and (1 399.88±376.44) min·μg/mL; AUC0-∞ were (1 710.61±309.40) and (1 417.29±383.21) min·μg/mL; t1/2 were (30.92±6.41) and (22.37±7.59) min. Conclusion Pharmacokineties of pantoprazole enantiomers has a stereoseleetive character in rats, which provide reference for clinical rational application of chiral drug pantoprazole sodium."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2016年第31卷第8期 >2016,31(8):1141-1145. DOI:10.7501/j.issn.1674-5515.2016.08.004
上一篇 | 下一篇

泮托拉唑鈉在大鼠體內(nèi)藥動(dòng)學(xué)研究

Pharmacokinetics of pantoprazole sodium in rats

發(fā)布日期:2016-08-24